Phathom Pharmaceuticals Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 112

Employees

  • Stock Symbol
  • PHAT

Stock Symbol

  • Share Price
  • $11.87
  • (As of Tuesday Closing)

Phathom Pharmaceuticals General Information

Description

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 100 Campus Drive
  • Suite 102
  • Florham Park, NJ 07932
  • United States
+1 (877) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Phathom Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.87 $11.70 $6.07 - $17.02 $695M 58.5M 646K -$4.47

Phathom Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 365,659 409,646 365,958 487,879
Revenue 2,594 682 0 0
EBITDA (206,797) (166,925) (171,930) (136,615)
Net Income (246,630) (201,592) (197,723) (143,883)
Total Assets 356,499 413,842 164,810 189,431
Total Debt 150,045 139,030 97,070 91,341
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Phathom Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Phathom Pharmaceuticals‘s full profile, request access.

Request a free trial

Phathom Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing an
Biotechnology
Florham Park, NJ
112 As of 2022
00000
000000000 00000

000000

aboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehe
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 00000

000000

e et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ull
0000 000000000
Fremont, CA
000 As of 0000
00000
000000000 00 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Phathom Pharmaceuticals Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA 000 00000 000000000 00000
Ardelyx Formerly VC-backed Fremont, CA 000 00000 000000000 00 00000
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA 000 00000 000000000 00000
Cinclus Pharma Venture Capital-Backed Stockholm, Sweden 00 000.00 00000000 000.00
Aileron Therapeutics Formerly VC-backed Watertown, MA 0 00000 000000000 00000
You’re viewing 5 of 34 competitors. Get the full list »

Phathom Pharmaceuticals Executive Team (10)

Name Title Board Seat Contact Info
Terrie Curran President, Chief Executive Officer & Board Member
Azmi Nabulsi MD Founder & Chief Operating Officer, Operations
Joseph Hand JD Chief Administrative Officer
Martin Gilligan Chief Commercial Officer
Tom Harris Chief Development Sciences Officer
You’re viewing 5 of 10 executive team members. Get the full list »

Phathom Pharmaceuticals Board Members (11)

Name Representing Role Since
David Socks Self Founder & Board Member 000 0000
Frank Karbe Phathom Pharmaceuticals Board Member 000 0000
Heidi Kunz Phathom Pharmaceuticals Board Member 000 0000
James Topper Ph.D Frazier Healthcare Partners Board Member 000 0000
Mark Stenhouse Phathom Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Phathom Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Phathom Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Phathom Pharmaceuticals‘s full profile, request access.

Request a free trial

Phathom Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated December, 10, 2022

33.82 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Phathom Pharmaceuticals’s complete esg history, request access »

Phathom Pharmaceuticals FAQs

  • When was Phathom Pharmaceuticals founded?

    Phathom Pharmaceuticals was founded in 2018.

  • Who is the founder of Phathom Pharmaceuticals?

    Azmi Nabulsi MD is the founder of Phathom Pharmaceuticals.

  • Who is the CEO of Phathom Pharmaceuticals?

    Terrie Curran is the CEO of Phathom Pharmaceuticals.

  • Where is Phathom Pharmaceuticals headquartered?

    Phathom Pharmaceuticals is headquartered in Florham Park, NJ.

  • What is the size of Phathom Pharmaceuticals?

    Phathom Pharmaceuticals has 112 total employees.

  • What industry is Phathom Pharmaceuticals in?

    Phathom Pharmaceuticals’s primary industry is Biotechnology.

  • Is Phathom Pharmaceuticals a private or public company?

    Phathom Pharmaceuticals is a Public company.

  • What is Phathom Pharmaceuticals’s stock symbol?

    The ticker symbol for Phathom Pharmaceuticals is PHAT.

  • What is the current stock price of Phathom Pharmaceuticals?

    As of 18-Jun-2024 the stock price of Phathom Pharmaceuticals is $11.87.

  • What is the current market cap of Phathom Pharmaceuticals?

    The current market capitalization of Phathom Pharmaceuticals is $695M.

  • What is Phathom Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Phathom Pharmaceuticals is $2.59M.

  • Who are Phathom Pharmaceuticals’s competitors?

    Crinetics Pharmaceuticals, Ardelyx, Rhythm Pharmaceuticals, Cinclus Pharma, and Aileron Therapeutics are some of the 34 competitors of Phathom Pharmaceuticals.

  • What is Phathom Pharmaceuticals’s annual earnings per share (EPS)?

    Phathom Pharmaceuticals’s EPS for 12 months was -$4.47.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »